These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38636210)

  • 21. NICE's Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests.
    O'Mahony JF; Paulden M; McCabe C
    Pharmacoeconomics; 2021 Feb; 39(2):139-146. PubMed ID: 33462758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
    Claxton K; Martin S; Soares M; Rice N; Spackman E; Hinde S; Devlin N; Smith PC; Sculpher M
    Health Technol Assess; 2015 Feb; 19(14):1-503, v-vi. PubMed ID: 25692211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Getting their say, or getting their way? Has participation strengthened the patient "voice" in the National Institute for Clinical Excellence?
    Quennell P
    J Manag Med; 2001; 15(3):202-19. PubMed ID: 11547580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
    Littlejohns P; Barnett D; Longson C;
    Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The NICE cost-effectiveness threshold: what it is and what that means.
    McCabe C; Claxton K; Culyer AJ
    Pharmacoeconomics; 2008; 26(9):733-44. PubMed ID: 18767894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project.
    Baker R; Bateman I; Donaldson C; Jones-Lee M; Lancsar E; Loomes G; Mason H; Odejar M; Pinto Prades JL; Robinson A; Ryan M; Shackley P; Smith R; Sugden R; Wildman J;
    Health Technol Assess; 2010 May; 14(27):1-162. PubMed ID: 20525460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
    Tikhonova IA; Hoyle MW; Snowsill TM; Cooper C; Varley-Campbell JL; Rudin CE; Mujica Mota RE
    Pharmacoeconomics; 2017 Mar; 35(3):363-373. PubMed ID: 27752999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Financial interests of patient organisations contributing to technology assessment at England's National Institute for Health and Care Excellence: policy review.
    Mandeville KL; Barker R; Packham A; Sowerby C; Yarrow K; Patrick H
    BMJ; 2019 Jan; 364():k5300. PubMed ID: 30651227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Robot-assisted training compared with an enhanced upper limb therapy programme and with usual care for upper limb functional limitation after stroke: the RATULS three-group RCT.
    Rodgers H; Bosomworth H; Krebs HI; van Wijck F; Howel D; Wilson N; Finch T; Alvarado N; Ternent L; Fernandez-Garcia C; Aird L; Andole S; Cohen DL; Dawson J; Ford GA; Francis R; Hogg S; Hughes N; Price CI; Turner DL; Vale L; Wilkes S; Shaw L
    Health Technol Assess; 2020 Oct; 24(54):1-232. PubMed ID: 33140719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products.
    Lee D; McCarthy G; Saeed O; Allen R; Malottki K; Chandler F
    Pharmacoecon Open; 2023 Mar; 7(2):175-187. PubMed ID: 36315388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020.
    Polak TB; Cucchi DGJ; Darrow JJ; Versteegh MM
    BMJ Open; 2022 Apr; 12(4):e058279. PubMed ID: 35396306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
    Hashem F; Calnan MW; Brown PR
    Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA.
    Goldman D; Lakdawalla D; Philipson TJ; Yin W
    Health Econ; 2010 Oct; 19(10):1109-16. PubMed ID: 20842680
    [No Abstract]   [Full Text] [Related]  

  • 34. NICE's citizen's council: what do we ask them, and how?
    Dolan P; Tsuchiya A; Wailoo A
    Lancet; 2003 Sep; 362(9387):918-9. PubMed ID: 13678989
    [No Abstract]   [Full Text] [Related]  

  • 35. The ethics of grandfather clauses in healthcare resource allocation.
    Wester G; Gibson Rand LZ; Lu C; Sheehan M
    Bioethics; 2021 Feb; 35(2):151-160. PubMed ID: 33043477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.
    Lord J; Willis S; Eatock J; Tappenden P; Trapero-Bertran M; Miners A; Crossan C; Westby M; Anagnostou A; Taylor S; Mavranezouli I; Wonderling D; Alderson P; Ruiz F
    Health Technol Assess; 2013 Dec; 17(58):v-vi, 1-192. PubMed ID: 24325843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of NICE's recommendations, 1999-2005.
    Raftery J
    BMJ; 2006 May; 332(7552):1266-8. PubMed ID: 16735341
    [No Abstract]   [Full Text] [Related]  

  • 38. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
    Bullement A; Meng Y; Cooper M; Lee D; Harding TL; O'Regan C; Aguiar-Ibanez R
    J Med Econ; 2019 Mar; 22(3):205-214. PubMed ID: 30422080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors.
    Chen G; Peirce V; Marsh W
    Value Health; 2020 Oct; 23(10):1300-1306. PubMed ID: 33032773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.